Caligan Partners LP: 13F holdings
CIK 17274922026Q2
| Positions | 26 |
|---|
| Reported value | $2.1bn |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 26 (+0 vs prior quarter) |
|---|
| Reported value | $2.1bn (+41.5%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| LQDA LIQUIDIA CORPORATION | 8,118,892 | $647.3m | 30.5% |
| RVMD REVOLUTION MEDICINES INC | 1,961,795 | $367.4m | 17.3% |
| ABVX ABIVAX SA | 1,557,924 | $207.6m | 9.8% |
| PCVX VAXCYTE INC | 2,188,636 | $127.2m | 6.0% |
| EXEL EXELIXIS INC | 1,553,262 | $84.5m | 4.0% |
| TNGX TANGO THERAPEUTICS INC | 2,500,103 | $78.2m | 3.7% |
| AVTX AVALO THERAPEUTICS INC | 3,163,866 | $58.5m | 2.8% |
| XENE XENON PHARMACEUTICALS INC | 889,944 | $53.7m | 2.5% |
| ADMA ADMA BIOLOGICS INC | 5,725,007 | $47.9m | 2.3% |
| LBRX LB PHARMACEUTICALS INC | 1,438,070 | $46.7m | 2.2% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1727492")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples